Market share and costs of biologic therapies for inflammatory bowel disease in the USA

ConclusionThe vast majority of costs allocated to out‐patient IBD medications in the USA is attributed to increasing use of biologic therapies despite the relative minority of biologic‐taking patients.

Source: Alimentary Pharmacology and Therapeutics - November 22, 2017 Category: Drugs & Pharmacology Authors: H. Yu, D. MacIsaac, J. J. Wong, Z. M. Sellers, A. A. Wren, R. Bensen, C. Kin, K. T. Park Tags: ORIGINAL ARTICLE Source Type: research